Digoxin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1975
- First approval year
- 1975
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Digoxin
- Molecular weight
- 780.95
- Structure (SMILES)
- C[C@H]1O[C@@H](O[C@H]2[C@@H](O)C[C@H](O[C@H]3[C@@H](O)C[C@H](O[C@H]4CC[C@@]5(C)[C@H](CC[C@@H]6[C@@H]5C[C@@H](O)[C@]5(C)[C@@H](C7=CC(=O)OC7)CC[C@]65O)C4)O[C@@H]3C)O[C@@H]2C)C[C@H](O)[C@@H]1O
- digamex
- Digamex
- digoxin
- Digoxin
- digoxin pediatric
- Digoxin pediatric
- lanoxicaps
- Lanoxicaps
- lanoxin
- Lanoxin
- lanoxin 125
- lanoxin pediatric
- Lanoxin pediatric
- lanoxin pg
- Lanoxin-125
- Lanoxin-pg
- 3 beta o 2 6 dideoxy beta d ribo hexopyranosyl 1 4 o 2 6 dideoxy beta d ribo hexopyranosyl 1 4 2 6 dideoxy beta d ribo hexopyranosyl oxy 12 beta 14 dihydroxy 5 beta card 20 22 enolide
- 3.BETA.-((O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-12.BETA.,14-DIHYDROXY-5.BETA.-CARD-20(22)-ENOLIDE
- ab 106 digoxin
- card 20 22 enolide 3 o 2 6 dideoxy beta d ribo hexopyranosyl 1 4 o 2 6 dideoxy beta d ribo hexopyranosyl 1 4 2 6 dideoxy beta d ribo hexopyranosyl oxy 12 14 dihydroxy 3 beta 5 beta 12 beta
- CARD-20(22)-ENOLIDE, 3-((O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-O-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL-(1->4)-2,6-DIDEOXY-.BETA.-D-RIBO-HEXOPYRANOSYL)OXY)-12,14-DIHYDROXY-,(3.BETA.,5.BETA.,12.BETA.)-
- digoxin
- Digoxin
- Digoxin (0.25mg)
- Digoxin (dual therapy)
- Digoxin (monotherapy)
- Digoxin (Part B)
- Digoxin (transabdominal administration)
- Digoxin (transvaginal administration)
- DIGOXIN [EP MONOGRAPH]
- DIGOXIN [HSDB]
- DIGOXIN [IARC]
- digoxin [INN]
- DIGOXIN [JAN]
- DIGOXIN [MART.]
- DIGOXIN [MI]
- DIGOXIN [ORANGE BOOK]
- DIGOXIN [USP MONOGRAPH]
- DIGOXIN [USP-RS]
- DIGOXIN [VANDF]
- Digoxin [WHO-DD]
And 53 more, listed on the interactive page.
- ATC classification codes
- C01AA05
Sources for recorded values
- CAS registry numbers
- 20830-75-5
- ChEMBL ID
- CHEMBL1751
- InChIKey
- LTMHDMANZUZIPE-PUGKRICDSA-N
- PubChem compound IDs
- 2724385
- RxNorm IDs (RxCUI)
- 3407
- FDA ingredient codes (UNII)
- 73K4184T59
- Applicant
- AZURITY
- Approval date
- 16 Nov 1954
- Application number
- NDA009330
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Pharmacology name
- digoxin
- Type
- Natural product
- Drug name stem
- -oxin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- sodium/potassium-transporting ATPase subunit α-1
- Gene symbol
- ATP1A1
- Protein identifier
- P05023
- Primary target
- Yes
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
- Protein identifier
- P05023
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
- Protein identifier
- P05026
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
- Protein identifier
- P13637
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
- Protein identifier
- P14415
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
- Protein identifier
- P50993
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
- Protein identifier
- P54709
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
- Protein identifier
- P54710
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
- Protein identifier
- Q13733
Open Targets mechanisms
- Mechanism
- Sodium/potassium-transporting ATPase inhibitor
- Action type
- Inhibitor
- Target
- Sodium/potassium-transporting ATPase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- ATP1A1|ATP1B1|ATP1A3|ATP1B2|ATP1A2|ATP1B3|FXYD2|ATP1A4
- Protein identifier
- P05023|P05026|P13637|P14415|P50993|P54709|P54710|Q13733
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Heart Failure
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Epilepsy
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000474
- Subject identifier
- D004827
- Condition
- Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Sarcoma, Kaposi
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000558
- Subject identifier
- D012514
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Cytomegalovirus Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001062
- Subject identifier
- D003586
- Condition
- Obesity
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Keratosis, Actinic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002496
- Subject identifier
- D055623
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Hepatitis C
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003047
- Subject identifier
- D006526
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Heart Failure
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Pain
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003869
- Subject identifier
- D001943
- Condition
- Substance-Related Disorders
- Highest recorded phase
- 1
- Condition identifier
- EFO:0003890
- Subject identifier
- D019966
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
And 16 more, listed on the interactive page.
- Condition identifier
- EFO_0000275
- Condition identifier
- EFO_0000319
- Condition identifier
- EFO_0000373
- Condition identifier
- EFO_0000400
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000474
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000558
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000668
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000685
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000764
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001062
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 1
- Condition identifier
- EFO_0002496
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003060
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003144
- Condition identifier
- EFO_0005207
- Condition identifier
- EFO_0006859
- Condition identifier
- EFO_1001249
- Highest recorded phase
- 2
- Condition identifier
- HP_0001395
- Highest recorded phase
- 2
- Condition identifier
- HP_0003826
- Condition identifier
- HP_0004755
- Highest recorded phase
- 3
- Condition identifier
- HP_0011675
- Condition identifier
- HP_0011675
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001134
- Highest recorded phase
- 1
And 31 more, listed on the interactive page.
- Event
- acute kidney injury
- Reports
- 288
- Reporting signal score
- 261.221
- Event
- allergic myocarditis
- Reports
- 12
- Reporting signal score
- 60.7637
- Event
- anorexia
- Reports
- 56
- Reporting signal score
- 87.8859
- Event
- arrhythmia
- Reports
- 105
- Reporting signal score
- 134.861
- Event
- asthenia
- Reports
- 371
- Reporting signal score
- 228.941
- Event
- atrial fibrillation
- Reports
- 432
- Reporting signal score
- 756.93
- Event
- atrial flutter
- Reports
- 63
- Reporting signal score
- 122.585
- Event
- atrial tachycardia
- Reports
- 46
- Reporting signal score
- 145.265
- Event
- atrioventricular block
- Reports
- 93
- Reporting signal score
- 224.021
- Event
- atrioventricular block complete
- Reports
- 100
- Reporting signal score
- 245.028
- Event
- atrioventricular block first degree
- Reports
- 73
- Reporting signal score
- 191.549
- Event
- atrioventricular block second degree
- Reports
- 58
- Reporting signal score
- 152.567
- Event
- blood creatinine increased
- Reports
- 133
- Reporting signal score
- 116.892
- Event
- blood potassium increased
- Reports
- 65
- Reporting signal score
- 108.322
- Event
- blood urea increased
- Reports
- 57
- Reporting signal score
- 71.4521
- Event
- bradyarrhythmia
- Reports
- 85
- Reporting signal score
- 313.914
- Event
- bradycardia
- Reports
- 977
- Reporting signal score
- 2,625.67
- Event
- bundle branch block left
- Reports
- 35
- Reporting signal score
- 67.3564
- Event
- cardiac arrest
- Reports
- 91
- Reporting signal score
- 107.228
- Event
- cardiac failure
- Reports
- 172
- Reporting signal score
- 216.26
- Event
- cardiac failure chronic
- Reports
- 27
- Reporting signal score
- 58.9538
- Event
- cardiac murmur
- Reports
- 78
- Reporting signal score
- 174.245
- Event
- cardiogenic shock
- Reports
- 45
- Reporting signal score
- 67.6308
- Event
- cardiospasm
- Reports
- 15
- Reporting signal score
- 67.899
- Event
- confusional state
- Reports
- 201
- Reporting signal score
- 137.788
And 41 more, listed on the interactive page.
- NCT00000556
- NCT00712465
- NCT01047566
- NCT02391337
- NCT02489786
- NCT03718273
- NCT05287191
- NCT05540600
- NCT00281021
- NCT00390546
- NCT00504413
- NCT00650910
- NCT00904176
- NCT01103622
- NCT01147718
- NCT01436201
- NCT06293742
- NCT00991783
- NCT01005602
- NCT01699776
- NCT02046044
- NCT02544815
- NCT02797145
- NCT03783429
- NCT01056874
And 53 more, listed on the interactive page.
- Dose
- Up to 500mcg per site
- Route
- Intravenous
- How often
- Once daily
- Administer over at least 5 minutes
- Avoid bolus administration
- Consider dose reduction before electrical cardioversion
- Inject deep into muscle and massage after
- Hydrogen bond acceptors
- 14
- Hydrogen bond donors
- 6
- Polar surface area
- 203.06
- Calculated partition coefficient (ALogP)
- 2.22
- Calculated partition coefficient (XLogP)
- 1.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 3
- Rotatable bonds
- 7
- Heavy atoms
- 55
- Molecular formula
- C41H64O14
- Monoisotopic mass
- 780.42960671
- Natural product
- Yes
- 0054-0057
- 0115-9811
- 0115-9822
- 0143-1240
- 0143-1241
- 0404-9850
- 0615-8202
- 0641-1410
- 0641-6184
- 0781-3059
- 0904-5921
- 0904-5922
- 10135-747
- 10135-748
- 50268-238
- 51655-403
- 59212-240
- 59212-242
- 59212-249
- 59651-436
- 59651-437
- 59651-438
- 60429-100
- 60687-858
- 60687-869
And 34 more, listed on the interactive page.
- Recorded assays
- 4,060
- Active assays
- 672
- Confirmatory
- Other
- Screening
- Summary
- Anti-Arrhythmia Agents
- Cardiotonic Agents
- Enzyme Inhibitors
These details could not be displayed.
Related records
Trials (325)
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
- A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of ACH-0145228
- A Drug Interaction Study of Albiglutide and Digoxin
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
Approved for (4)
- Atrial fibrillation
- Cardiovascular disorder
- Congestive heart failure
- Heart failure
In development for (33)
- Actinic keratosis Phase 2
- Acute myeloid leukemia Phase 1
- Breast cancer Phase 2
- Breast neoplasm Phase 2
- Cardiac rhythm disease Phase 3
- Chronic hepatitis B virus infection Phase 1
- Chronic obstructive pulmonary disease Phase 1
- Cytomegalovirus infection Phase 1
- Depressive disorder Phase 1
- Diabetes mellitus Phase 1
- Drug dependence Phase 1
- Epilepsy Phase 1
- Essential hypertension Phase 1
- Exocrine pancreatic carcinoma Phase 2
- Head and neck cancer Phase 1
- Hepatitis C virus infection Phase 1
- Hereditary angioedema Phase 1
- HIV infectious disease Phase 1
- Influenza Phase 1
- Kaposi's sarcoma Phase 2
Other linked conditions (2)
- Congenital heart disease
- Severe pre-eclampsia
Targets (8)
- ATP1A1 Sodium/potassium-transporting ATPase inhibitor
- ATP1A2 Sodium/potassium-transporting ATPase inhibitor
- ATP1A3 Sodium/potassium-transporting ATPase inhibitor
- ATP1A4 Sodium/potassium-transporting ATPase inhibitor
- ATP1B1 Sodium/potassium-transporting ATPase inhibitor
- ATP1B2 Sodium/potassium-transporting ATPase inhibitor
- ATP1B3 Sodium/potassium-transporting ATPase inhibitor
- FXYD2 Sodium/potassium-transporting ATPase inhibitor